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Abstract
Background: The management of hilar cholangiocarcinoma has evolved over time and extended liver
resection, including the caudate lobe, and major vascular resection and extended lymphadenectomy
have become established practice. The benefit of vascular resection has not been investigated.
Methods: A systematic search of the MEDLINE and EMBASE databases was used to identify studies.
A systematic review and a meta-analysis of the available studies were conducted according to PRISMA
guidelines. Odds ratios were calculated using the Mantel–Haenszel method. Primary outcome variables
assessed included morbidity, mortality, vascular complications and the effect of vascular resection on
longterm survival.
Results: Of 411 search results, only 24 studies reported the results of vascular resection in hilar
cholangiocarcinoma. Meta-analysis showed increased morbidity and mortality with hepatic artery resec-
tion. Portal vein resection was achievable with no impact on postoperative mortality. Vascular resection
did not improve negative margin rates and had no impact on longterm survival.
Conclusions: Portal vein resection does not preclude curative resection; however, it is not routinely
recommended unless there is suspicion of tumour invasion. There was no proven survival advantage with
portal vein resection. Arterial resection results in higher morbidity and mortality with no proven benefit.
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Introduction
Cancer of the hepatic hilum accounts for 50–80% of biliary malig-
nancies.1,2 Surgical resection of hilar cholangiocarcinoma offers
patients the best chance of longterm survival. The first resection
was reported by Brown and Myers in 1954.1 Combined portal vein
and liver resection for locally advanced hilar cholangiocarcinoma
was first successfully performed in 1965 at the Cancer Institute
Hospital in Tokyo. The patient in question underwent right hepa-
tectomy, en bloc excision of the bile duct and portal vein with
end-to-end reconstruction.2 This was followed by further
attempts to perform such radical resections. Improvements in
microvascular anastomoses and experience with liver transplants
have made it possible to perform resection and reconstruction of
both the hepatic artery and portal vein.3,4 These technical
advances demonstrate that combined resection of the portal vein
improves the rate of radical resection for hilar cholangiocarci-
noma and perhaps significantly prolongs survival.5–9 Actual
tumour invasion of the portal vein documented on pathological
examination is associated with poor survival.8
Median survival following resection is 11–38 months and the
5-year survival rate is 20–40%.10,11 The introduction of hepatec-
tomy with hilar resection has increased the rate of curative resec-
tion and the total number of patients who are amenable to
surgical resection.5 This radical approach is facilitated by the fact
that the left hepatic duct extends 2–5 cm outside the hepatic
parenchyma. This makes it possible to achieve a negative margin
and to perform an extrahepatic biliary reconstruction. Resectabil-
ity, negative margin and survival rates are improved when the
caudate lobe is resected en bloc with the tumour.12
Since the introduction of portal vein embolization (PVE),
preoperative hypertrophy of the future remnant liver, induced by
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unilateral PVE, has been shown to reduce the risk for postopera-
tive liver failure attributable to a small liver remnant.13
Recently, there has been increasing evidence to support the use
of en bloc vascular resection and reconstruction of the main
portal vein and the contralateral hepatic artery or both, along with
the resected tumour, and a hemi-hepatectomy when the tumour is
thought on radiological assessment to involve these vessels.6–9 This
is based on the fact that radical surgical resection is the best
treatment option for hilar cholangiocarcinoma; negative-margin
(R0) resection provides acceptable 5-year survival of 20–40%.14 In
addition, experience in vascular reconstruction during liver trans-
plantation has been translated safely to oncological resections.
This review investigates the safety and efficacy of vascular resec-
tion and reconstruction in combination with hepatic and bile duct
resection, with particular reference to immediate outcome meas-
ures and survival benefits.
Materials and methods
Search and study selection
A search was conducted of MEDLINE (1966 to June 2012),
PubMed (1950–2011) and EMBASE (1980 to June 2012), using
the MESH (medical subject headings) terms ‘hilar cholangiocar-
cinoma’, ‘vascular resection’, ‘portal vein’ and ‘hepatectomy’; com-
binations of these terms were also used. Abstracts of the studies
identified were reviewed, and studies that addressed vascular
resection along with some form of hepatectomy and radical exci-
sion of the bile duct were retrieved and assessed for suitability for
systematic review.
Eligibility criteria
Clinical reports that dealt with hilar cholangiocarcinoma were
reviewed and included only if the management included hepate-
ctomy with radical excision of the bile duct and lymphadenec-
tomy in patients with encasement of the vessels in whom surgery
included resection and reconstruction of the portal vein, with or
without concomitant resection and reconstruction of the contral-
ateral or main hepatic artery. Studies that reported vascular resec-
tion with local excision or pancreatoduodenectomy for lower bile
duct cancers were excluded. Because of the absence of randomized
trials in this area, the review and meta-analysis were conducted on
cohort studies that reported primary outcome measures (mortal-
ity, morbidity, 5-year survival, specific complications related to
vascular reconstruction), in addition to bile leak and liver failure
as significant complications of this radical procedure. The studies
were assessed using the Newcastle–Ottawa Quality Assessment
Scale for Cohort Studies15 and studies thought to be suitable were
included in the meta-analysis.
Search strategy
1 *Cholangiocarcinoma/or *bile duct neoplasms/
2 *Hepatic artery/or *portal vein/
3 *Vascular surgical procedures/
4 *Klatskin’s tumour/or *cholangiocarcinoma/or *bile duct
neoplasms/or *hepatectomy/
5 1 or 4
6 2 or 3
7 5 and 6
8 Hepatectomy
9 7 and 8.
Data extraction
Relevant data concerned with the outcomes were collected inde-
pendently by two reviewers from the studies when these data were
directly available or were extracted from results that were reported
in percentages. These data included details of the number of
patients undergoing vascular resection, morbidity, mortality, vas-
cular complications, rates of R0 curative resection, 5-year survival
with and without vascular resection, and actual numbers of cases
of true invasion of the vessels by the cancer. Differences in the data
were resolved by consensus.
Statistical analysis
The relevant outcomes were entered in a meta-analysis using
RevMan 5.016 developed by the Cochrane Collaboration. Both
random- and fixed-effects models were used. The random-effects
model was used for analysis and its results reported as this model
was thought to produce more robust results. Data were entered as
categorical variables and analysed using the Mantel–Haenszel test.
Results were expressed as forest plots and summarized with odd
ratios (ORs) and 95% confidence intervals (CIs). A P-value of
<0.05 was considered to indicate statistical significance and the
results were summarized using the OR. Sensitivity analysis was
performed by excluding and including studies whenever hetero-
geneity was encountered; studies that seemed to be outliers and
had significant effects on the results were excluded. Publication
bias was assessed using a funnel plot.
Statistical heterogeneity in the results of the meta-analysis was
assessed by graphical presentations of the CIs on forest plots and
by performing a chi-squared test for heterogeneity. The I2 statistic
was used to quantify heterogeneity; P-values of <0.100 were
regarded as indicating significance. Funnel plots for publication
bias were constructed and outlying studies were excluded.
Results
Figure 1 shows the selection of articles according to PRISMA (pre-
ferred reporting items for systematic reviews and meta-analyses)
guidelines.17
Thirty-seven articles were retrieved and assessed by two review-
ers; 24 articles were found to be suitable for inclusion in the review
and meta-analysis. These reports covered a total of 2457 patients
who underwent resections of hilar cholangiocarcinoma, 669 of
whom underwent vascular resection. Five-year survival was
20–56%, morbidity was 22–88%, and mortality was 2–15%. No
randomized trials comparing vascular resection with no vascular
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resection were identified; all studies were cohort studies. Rates of
curative R0 resection varied from 36% to 88% (Table 1). Patho-
logical analysis of the resected specimens showed that rates of
actual tumour invasion of the vessels were 22–88% (Table 2).
Description of included trials
All included studies reported outcomes in a cohort of patients
with hilar cholangiocarcinoma of different stages. Patients who
were thought to have involvement of vessels in the hilum under-
went vascular resection with reconstruction; venous resection was
performed more often than arterial resection and reconstruction.
The methodological quality of the studies was considered
adequate based on the Newcastle–Ottawa scale for the meta-
analysis of cohort studies.15 All included studies reported 5-year
survival; data on vascular complications, mortality related to vas-
cular resection and liver failure were variable. The number of
studies reporting these outcome measures was suitable for a
meta-analysis.
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Figure 1 Flow chart showing the study selection process
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Vascular complications
Occurrences of vascular complications were compared between
patients who did and did not undergo vascular resection. These
complications included thrombosis of the portal vein or hepatic
artery, stenosis of these vessels, and pseudoaneurysms. The meta-
analysis revealed higher complication rates in patients who under-
went vascular resection (OR 8.8, 95% CI 3.5–22;P< 0.0001) (Fig. 2).
Mortality
Thirteen studies6–8,18–27 reported the difference in mortality
between patients who did and did not undergo vascular resection.
The meta-analysis showed significantly higher mortality among
patients who underwent vascular resection (OR 2.07, 95% CI
1.21–3.57; P = 0.008) (Fig. 3).
Overall morbidity
Only three studies26–28 reported the difference in overall morbidity
between patients who did and did not undergo vascular resection.
Meta-analysis of these studies showed no difference in morbidity
between the two groups; however, the sample size was small. Given
that higher mortality occurred in the vascular resection group, a
definitive conclusion was not possible (Fig. 4).
Mortality with arterial resection
In order to further analyse the risk for death following arterial
resection, mortality rates were compared between patients who
underwent arterial resection and reconstruction in addition to
portal vein resection, and those who underwent portal vein but not
arterial resection.7,19,22–24,26,27 A meta-analysis of data on this outcome
showed higher mortality rates in patients who underwent arterial
resection (OR 4.48, 95% CI 1.97–10.16; P = 0.0003) (Fig. 5).
Liver failure
A meta-analysis of data from studies that reported differences in
liver failure between vascular resection patients and patients
Table 1 Studies included in the current meta-analysis
Study Patients,
n
Vascular
resection, n
Morbidity,
%
Mortality,
%
5-year
survival, %
R0,
%
R1,
%
R0 rate with
vascular resection,
%
Muñoz et al. 20027 28 10 25 3 23 – – –
Igami et al. 201022 298 111 43 2 42 52 32 66
Song et al. 200925 259 51 54 9.6 29.3 29.3 17 71.8
Young et al. 201023 51 21 75 8 20 40 2 57
Kondo et al. 200421 42 14 48 0 – – – 95
Miyazaki et al. 201018 107 25 – 2 – 33 21 59
Neuhaus et al. 200331 133 – – – – 38 18 –
Lee et al. 200024 111 29 22 6.3 24 77
Nimura et al. 200034 142 43 48.6 9 25 26 16 61
Nagino et al. 201019 261 50 54 2 30 40.7 0 54
Ebata et al. 20038 160 52 84 9.6 37 – – –
Hemming et al. 201120 95 42 36 5 43 50 0 84
Hemming et al. 20059 53 23 40 9 35 45 0 80
Baton et al. 200730 59 5 42 5 20 28 6 67
Nagino et al. 200145 105 33 81 9.5 – – – –
Magriaga 199828 28 9 32 14 8 11 0 50
Hidalgo 200814 44 17 66 6.8 41 45 26 45
Shimada et al. 200326 39 15 71 6.7 56 50 10 50
Neuhaus et al. 19996 66 23 56 3 22 42 9 61
Edmond 198943 13 5 69 15 – – – 46
Lygidakis 198844 13 7 – 15 – – – 46
Klempnauer et al. 199729 125 41 29.8 9.9 28 26 6.8 73
Miyazaki et al. 200727 161 43 39 7 36 0 36
Table 2 Invasion of the portal vein confirmed by histology
Study Positive for
invasion, n (%)
Portal vein
resection, n
Song et al. 200925 28 (54%) 51
Ebata et al. 20038 36 (69%) 52
Nagino et al. 201019 44 (80%) 50
Muñoz et al. 20027 5 (50%) 10
Hemming 201120 17 (40%) 42
Neuhaus et al. 19996 5 (22%) 23
Miyazaki et al. 200727 38 (88%) 44
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Study 
Hidalgo 2008
Igami 2010
Lee 2000
Miyazaki 2007
Miyazaki 2010
Munoz 2002
Nagino 2001
Shimada 2003
Song 2009
Young 2010
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 5.80, d.f. = 9 (P = 0.76); I² = 0%
Test for overall effect: Z = 4.65 (P < 0.00001)
Events
2
5
5
2
1
3
1
3
3
1
26
Total
17
111
29
43
28
10
33
15
51
21
358
Events
1
0
0
0
0
0
2
0
0
0
3
Total
27
187
82
118
79
18
72
24
208
30
845
Weight
13.6%
10.0%
9.8%
9.0%
8.1%
8.9%
14.2%
9.1%
9.5%
8.0%
100.0%
OR (95% CI)
3.47 (0.29-41.53)
19.37 (1.06-353.66)
37.04 (1.98-693.67)
14.28 (0.67-303.55)
8.67 (0.34-219.21)
17.27 (0.79-376.54)
1.09 (0.10-12.51)
13.72 (0.66-286.96)
30.09 (1.53-592.23)
4.46 (0.17-115.02)
8.82 (3.52-22.06)
Vascular resection No vascular resection M–H random effects M–H random effects
OR (95% CI)
0.01 0.1 1 10 100
Vascular resection No vascular resection
˜
Figure 2 Vascular complications in patients with and without vascular resection. M–H, Mantel–Haenszel test; OR, odds ratio; 95% CI, 95%
confidence interval
Study
Ebata 2003
Hemming 2011
Igami 2010
Kondo 2004
Lee 2000
Miyazaki 2007
Miyazaki 2010
Munoz 2002
Nagino 2001
Neuhaus 1999
Shimada 2003
Song 2009
Young 2010
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.15; Chi² = 13.23, d.f. = 11 (P = 0.28); I² = 17%
Test for overall effect: Z = 2.64 (P = 0.008)
Events
5
1
5
0
3
6
2
1
3
4
2
5
1
38
Total
52
42
111
14
29
43
28
10
33
23
15
51
21
472
Events
10
4
1
0
4
5
0
0
7
2
2
6
3
44
Total
108
53
187
23
82
118
79
18
72
43
24
208
30
1045
Weight
15.9%
5.3%
5.6%
9.7%
13.8%
2.9%
2.6%
11.3%
7.8%
6.0%
14.1%
4.9%
100.0%
OR (95% CI) OR (95% CI)
1.04 (0.34-3.22)
0.30 (0.03-2.78)
8.77 (1.01-76.10)
Not estimable
2.25 (0.47-10.72)
3.66 (1.06-12.71)
15.00 (0.70-322.49)
5.84 (0.22-157.58)
0.93 (0.22-3.84)
4.32 (0.73-25.65)
1.69 (0.21-13.50)
3.66 (1.07-12.51)
0.45 (0.04-4.65)
2.07 (1.21-3.57)
Vascular resection  No vascular resection M–H random effects M–H random effects
0.01 0.1 1 10 100
Vascular resection No vascular resection
˜
Figure 3 Mortality rates in patients with and without vascular resection. M–H, Mantel–Haenszel test; OR, odds ratio; 95% CI, 95%
confidence interval
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without vascular resection showed no significant increase in liver
failure after vascular resection.8,19,25–27 However, this is subject to
variations in definitions of liver failure (Fig. 6).
Survival in patients with negative and positive
resection margins
Curative resection with negative pathologic margins provides the
best chance for longterm survival. Reported 5-year survival rates
in patients with a pathological R0 margin in this review were
11–52%, which is significantly better than the 0–32% rates
reported for patients who had a pathological R1 margin with no
macroscopic residual disease (Fig. 7).
It was not clearly evident that adding vascular resection to a
radical resection of the bile duct with hepatectomy and lymph
node dissection improves longterm survival in hilar cholangiocar-
cinoma. In fact, the current meta-analysis shows that 5-year sur-
vival rates were lower in those who underwent vascular resection
(25% versus 39%; OR 1.88, 95% CI 1.22–2.90; P = 0.004) (Fig. 8).
A review of the reasons for this established that patients who
underwent vascular resection had significantly higher rates of
locally advanced disease (T3 and T4). Most of the studies included
did not analyse nodal staging and therefore it was not possible to
adjust for nodal status in the current analysis, although this factor
strongly affects longterm survival. In addition, there was signifi-
cant statistical heterogeneity among the studies included.
R0 margin status with vascular resection
Four studies6,8,25,27 reported the pathological margins of specimens
resected in patients who did and did not undergo vascular resec-
tion. A meta-analysis of these studies showed no significant dif-
Study
Madariaga 1998
Miyazaki 2007
Shimada 2003
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.08; Chi² = 2.39, d.f. = 2 (P = 0.30); I² = 16%
Test for overall effect: Z = 1.32 (P = 0.19)
Events
5
20
10
35
Total
9
43
15
67
Events
4
42
17
63
Total  Weight
19
118
24
161
15.3%
62.4%
22.3%
100.0%
OR (95% CI) OR (95% CI)
4.69 (0.84-26.08)
1.57 (0.78-3.19)
0.82 (0.21-3.30)
1.61 (0.80-3.25)
Vascular resection No vascular resection M–H random effects M–H random effects
0.01 0.1 1 10 100
Vascular resection No vascular resection
Figure 4 Overall morbidity rates in patients with and without vascular resection. M–H, Mantel–Haenszel test; OR, odds ratio; 95% CI, 95%
confidence interval
Study 
Igami 2010
Lee 2000
Miyazaki 2007
Miyazaki 2010
Munoz 2002
Nagino 2001
Shimada 2003
Young 2010
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 6.23, d.f. = 7 (P = 0.51); I² = 0%
Test for overall effect: Z = 3.58 (P = 0.0003)
Events
1
1
3
1
1
1
1
1
10
Total
53
4
9
3
4
5
6
5
89
Events
5
6
8
1
0
9
2
3
34
Total
245
107
127
104
18
100
24
40
765
Weight
14.3%
11.6%
27.6%
7.0%
5.8%
12.8%
10.0%
10.9%
100.0%
0.92 (0.11-8.07)
5.61 (0.50-62.37)
7.44 (1.56-35.39)
51.50 (2.31-1148.91)
15.86 (0.53-474.38)
2.53 (0.25-25.11)
2.20 (0.17-29.31)
3.08 (0.26-37.08)
4.48 (1.97-10.16)
Hepatic artery resection No arterial resection M–H random effects
0.01 0.1 1 10 100
Arterial resection No resection
OR (95% CI)
M–H random effects
OR (95% CI)
˜
Figure 5 Mortality in patients with and without hepatic artery resection and reconstruction. M–H, Mantel–Haenszel test; OR, odds ratio; 95%
CI, 95% confidence interval
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ference in the rates of R0 resection between the two groups
(Fig. 9). Venous invasion was reported to have occurred in
22–88% of patients (Table 2) and it may be that the addition of
venous resection increases the rate of R0 resection. However, the
relevant data were insufficient to support a meta-analysis.
Arterial resection and leak from hepaticojejunostomy
Three studies8,26,27 reported the difference between patients who
did and did not undergo arterial resection in the incidence of leaks
from a hepaticojejunostomy. A meta-analysis of these studies
showed a higher risk for leak in arterial resection; however, this
Study 
Ebata 2003
Miyazaki 2007
Nagino 2001
Shimada 2003
Song 2009
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.02; Chi² = 4.26, d.f. = 4 (P = 0.37); I² = 6%
Test for overall effect: Z = 0.54 (P = 0.59)
Events
14
8
9
2
1
34
Total
52
43
33
15
51
194
Events
21
18
20
2
21
82
Total  Weight
108
118
72
24
208
530
35.8%
26.5%
26.2%
5.6%
5.8%
100.0%
1.53 (0.70-3.32)
1.27 (0.51-3.18)
0.97 (0.39-2.46)
1.69 (0.21-13.50)
0.18 (0.02-1.36)
1.15 (0.70-1.88)
Vascular resection No vascular resection
0.01 0.1 1 10 100
Favours resection Favours no resection
OR (95% CI)
M–H random effects
OR (95% CI)
M–H random effects
Figure 6 Liver failure rates in patients with and without vascular resection. M–H, Mantel–Haenszel test; OR, odds ratio; 95% CI, 95%
confidence interval
Study
Madariaga 1998
Hemming 2005
Hemming 2011
Miyazaki 2007
Nagino 2010
Shimada 2003
Young 2010
Neuhaus 1999
Baton 2007
Klempnauer 1997
Hidalgo 2008
Miyazaki 2010
Nimura 2000
Song 2009
Igami 2010
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.68; Chi² = 37.71, d.f. = 14 (P = 0.0006); I² = 63%
Test for overall effect: Z = 5.06 (P < 0.00001)
Events
8
27
40
37
84
6
17
23
28
68
11
42
63
132
101
687
Total
9
42
80
59
141
13
29
40
39
92
21
63
86
186
196
1096
Events
9
11
15
102
120
12
21
20
18
27
11
34
47
61
70
578
Total
9
11
15
102
120
13
22
21
20
29
15
44
56
73
102
652
Weight
2.7%
3.3%
3.4%
3.5%
3.5%
4.6%
5.1%
5.2%
7.0%
7.5%
7.9%
10.8%
10.9%
11.8%
12.8%
100.0%
0.08 (0.00-1.40)
0.30 (0.01-8.35) 
0.03 (0.00-0.56)
0.01 (0.00-0.14)
0.01 (0.00-0.10)
0.07 (0.01-0.72)
0.07 (0.01-0.57)
0.07 (0.01-0.55)
0.28 (0.06-1.43)
0.21 (0.05-0.95)
0.40 (0.10-1.67)
0.59 (0.24-1.42)
0.52 (0.22-1.24)
0.48 (0.24-0.96)
0.49 (0.29-0.80)
0.21 (0.11-0.38)
R0 R1
0.01 0.1 1 10 100
R0 R1
OR (95% CI)
M–H random effects
OR (95% CI)
M–H random effects
Figure 7 Five-year survival in patients with R0 resection (negative margins) and R1 resection (microscopically involved margins). M–H,
Mantel–Haenszel test; OR, odds ratio; 95% CI, 95% confidence interval
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difference did not reach statistical significance. It is most likely
that this reflects the small number of patients included in the
meta-analysis (Fig. 10).
Survival with portal vein invasion
To assess the impact of actual invasion of vessels on survival, a
meta-analysis was performed on the studies that reported this
outcome. Five-year survival was similar regardless of whether or
not the vessels were invaded (Fig. 11).8,19,21,25,29
Discussion
The management of hilar cholangiocarcinoma is challenging and
it is often hard to achieve negative resection margins because of
the proximity of the bile duct to the hilar vessels and liver paren-
chyma. Surgical treatment has evolved significantly to result in
improvements in R0 resection and 5-year survival rates, mainly as
a result of the addition of major hepatectomy that includes the
caudate lobe.6,30–33 Local resection of the bile duct without liver
resection results in a high rate of margin positivity, with local
Study
Baton 2007
Ebata 2003
Hemming 2011
Hidalgo 2008
Igami 2010
Klempnauer 1997
Kondo 2004
Miyazaki 2007
Munoz 2002
Nagino 2010
Neuhaus 2003
Nimura 2000
Shimada 2003
Song 2009
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.33; Chi² = 29.75, d.f. = 13 (P = 0.005); I² = 56%
Test for overall effect: Z = 2.87 (P = 0.004)
Events
5
47
25
13
86
33
1
21
8
35
10
41
8
42
375
Total
7
52
42
17
111
37
14
34
10
50
34
43
10
51
512
Events
45
67
32
12
92
45
4
70
11
111
7
72
12
153
733
Total
52
108
53
27
187
61
26
118
18
211
14
99
16
208
1198
Weight
4.1%
8.2%
9.5%
6.0%
12.0%
7.0%
2.9%
9.9%
4.1%
10.9%
6.4%
5.4%
3.8%
9.9%
100.0%
0.39 (0.06-2.41)
5.75 (2.12-15.64)
0.97 (0.42-2.20)
4.06 (1.05-15.73)
3.55 (2.09-6.03)
2.93 (0.90-9.59)
0.42 (0.04-4.20)
1.11 (0.51-2.42)
2.55 (0.41-15.65)
2.10 (1.08-4.08)
0.42 (0.12-1.50)
7.69 (1.74-34.00)
1.33 (0.20-9.08)
1.68 (0.77-3.67)
1.88 (1.22-2.90)
Vascular resection No vascular resection
0.01 0.1 1 10 100
Vascular resection No vascular resection 
OR (95% CI)
M–H random effects
OR (95% CI)
M–H random effects
˜
Figure 8 Five-year survival in patients with and without vascular resection. M–H, Mantel–Haenszel test; OR, odds ratio; 95% CI, 95%
confidence interval
Study 
Ebata 2003
Miyazaki 2007
Neuhaus 1999
Song 2009
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.02; Chi² = 3.47, d.f. = 3 (P = 0.32); I² = 14%
Test for overall effect: Z = 1.62 (P = 0.10)
Events
35
25
14
36
110
Total
52
43
23
51
169
Events
91
77
26
150
344
Total  Weight
108
118
43
208
477
24.9%
28.7%
14.9%
31.6%
100.0%
0.38 (0.18-0.84)
0.74 (0.36-1.51)
1.02 (0.36-2.87)
0.93 (0.47-1.82)
0.71 (0.47-1.07)
Vascular resection  No vascular resection
0.01 0.1 1 10 100
Favours resection  Favours no resection
OR (95% CI)
M–H random effects
OR (95% CI)
M–H random effects
Figure 9 Rates of R0 resection in patients with and without vascular resection. M–H, Mantel–Haenszel test; OR, odds ratio; 95% CI, 95%
confidence interval
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recurrence occurring in up to 76% of patients after extrahepatic
bile duct resection.34 Miyazaki et al.35 described an improvement
in rates of curative resection from 45% in extrahepatic bile duct
resection to 75% in patients in whom liver resection was per-
formed routinely for hilar cholangiocarcinoma. There were no
5-year survivors among patients who underwent extrahepatic bile
duct resection only, whereas 5-year survival in patients also sub-
jected to liver resection was 27%.35 Nimura et al., from Nagoya
Medical School in Japan, reported similar survival results when
liver resection was employed.34 This radical surgical treatment
was extended to involve en bloc resection of the portal vein,
which is suggested to improve the extent of resection and sur-
vival.5,6 Resection of the portal vein was performed in most
instances by removing a certain length of vein in conjunction
with the tumour and effecting reconstruction by direct end-to-
end anastomosis.6,19,36,37
This review shows that resection with clear margins affords the
best chance for longterm survival in cholangiocarcinoma and
results in a reported 5-year survival of 41%.20 This resection
involves a major hepatectomy and radical clearance of the lymph
nodes, in addition to extrahepatic bile duct excision, an approach
that has proven to enhance longterm survival.6,21,38 This type of
resection may entail excision and reconstruction of the portal vein
with or without excision and reconstruction of the contralateral
or main hepatic artery. Routine portal vein resection may improve
survival, but this practice is not universally accepted.6,22 Resection
with clear margins is achievable in 36–95% of patients.22,23,36
Although portal vein resection is achievable with a minimal
increase in morbidity, resection of the hepatic artery is associated
with significant increases in morbidity and mortality, both of
which are related to the occurrence of vascular complications
arising from arterial resection and reconstruction. Portal vein
resection and reconstruction are also associated with the occur-
rence of vascular complications such as thrombosis requiring
reoperation, and late anastomotic strictures that manifest as
portal hypertension and variceal bleeding.24
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Figure 10 Anastomotic leak from (hepaticojejunostomy) in patients with and without arterial resection. M–H, Mantel–Haenszel test; OR, odds
ratio; 95% CI, 95% confidence interval
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True portal vein invasion in hilar cholangiocarcinoma is diffi-
cult to determine preoperatively. On computed tomography, the
loss of a clear plane, constriction of the vessel and occlusion are
regarded as evidence of venous invasion. Actual rates of venous
invasion on histopathological examination after resection vary
from 21% to 80%.6–8,18,19,25 Bile duct tumours are often adherent to
the surrounding tissues in the hepatoduodenal ligament, which
may be related to cholangitis complicating biliary obstruction. In
a series of 95 patients with hilar cholangiocarcinoma, Neuhaus
et al.6 reported overall 5-year survival of 22%, which increased to
65% in patients in whom clear margins were achieved by extend-
ing the liver resection and portal vein resection. It is not possible
to attribute this improvement to vascular resection because these
patients also underwent liver trisectionectomy, which has been
shown to increase survival, probably by increasing R0 resection
rates.6,30 Jarnagin et al. reported 5-year survival only in patients
subjected to liver resection.39 The impact of portal vein invasion
on survival is controversial. Although macroscopic invasion has a
negative impact on survival, microscopic invasion proved on mul-
tivariate analysis not to have an impact on survival.8 These find-
ings add to the complexity of decision making regarding portal
vein resection; however, it is logical to resect the vein if it is
suspected to be invaded by tumour. Moreover, en bloc resection
that involves vascular resection and reconstruction enables exci-
sion with a no-touch technique, which may reduce the shedding
of tumour cells and microembolization and is postulated to
improve survival with routine portal vein resection.6,19,29
Based on the finding that patients who undergo curative resec-
tion achieve better outcomes than those who do not undergo
resection, aggressive resection that involves the portal vein with or
without resection and reconstruction of the hepatic artery has
been introduced to achieve resectability rates of 85%.8,24 Arterial
resection, by contrast, has not been proven to add any survival
advantage. The present review found vascular resection to be asso-
ciated with increased risk for vascular complications and mortal-
ity. Subgroup analysis established that the increase in mortality
occurred as a result of the addition of arterial resection. Compli-
cations such as arterial thrombosis, haemorrhage and the forma-
tion of a pseudoaneurysm are likely to be responsible for the
increase in mortality. Patients subjected to arterial resection expe-
rienced higher rates of anastomotic leaks, although the difference
did not reach statistical significance.8,26,40 The performance of
arterial resection and reconstruction has been previously reported
to have dismal outcomes in patients subjected to concomitant
hepatectomy and bile duct resection.27,41,42 Gerhards et al. reported
death in five of nine patients (55.6%) who underwent hepatic
artery resection.41 Miyazaki et al. also reported a high mortality
rate of 33% in patients subjected to hepatic artery resection and
noted no 3-year survivors in this group.27
Neuhaus et al.6 reported 5-year survival rates of 72% in patients
subjected to routine portal vein resection and 52% in patients
without portal vein resection. Igami et al. found a similar
improvement in survival with routine portal vein resection.22
However, this experience was not reproduced in other stud-
ies.8,21,34,39 Ebata et al. have shown convincingly that the require-
ment for portal vein resection is associated with worse longterm
survival; on multivariate analysis, portal vein resection itself did
not worsen survival, but transluminal tumour invasion and posi-
tive margins were associated with a poorer prognosis.8 In the
present analysis, definitive conclusions on the effect of portal vein
resection on survival were not possible because of the heteroge-
neity of the studies and a tendency towards the selective resection
of the portal vein in patients with advanced disease (T3, T4) and
possibly with nodal metastases. Hepatic failure is a serious com-
plication of extended liver resection and the risk for liver failure in
patients undergoing vascular resection and reconstruction is
similar to that in patients subjected to liver resection without
vascular resection. In all of the studies included, PVE was under-
taken when necessary; the threshold for PVE was a future liver
remnant of < 30% of estimated total liver volume.20,39
Patients who retained microscopically positive margins
appeared to have a survival advantage over patients who did not
undergo surgical resection.37 This may lend credence to the sug-
gestion that resection should be attempted in hilar cholangiocar-
cinoma even if negative margins cannot be achieved and that it
may represent a useful palliative operation that results in 5-year
survival of up to 45%, provided every attempt is made not to leave
any macroscopic disease behind.37
Conclusions
The surgical treatment of hilar cholangiocarcinoma has signifi-
cantly changed the outcome of this disease in the last two decades.
The validity of resection of the involved portal vein is well estab-
lished and the procedure is likely to increase longterm survival.
Routine resection, however, remains controversial and there is
little possibility that randomized data will become available.
Without randomized trials, it is not possible to conclude whether
routine portal vein resection can improve the rate of R0 resection.
Although invasion of the portal vein has a negative impact on
survival, combined liver and portal vein resection may offer a
survival benefit to some patients with advanced cholangiocarci-
noma, who would otherwise be considered unresectable.
The addition of arterial resection and reconstruction is associ-
ated with increased morbidity and mortality without proven sur-
vival benefit or an improvement in the rate of clear margin
resections.
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